Mucosal and parenteral vaccination against acute and latent murine cytomegalovirus (MCMV) infection by using an attenuated MCMV mutant

Journal of Virology

Volumn 72, Issue 1, 1998, Pages 442-451

  Macdonald, Margaret R ^a   Li, Xi Yang ^b   Stenberg, Richard M ^c   Campbell, Ann E ^c   Virgin IV, Herbert W ^b  

^a Washington Univ School of Medicine ^*  (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VACCINATION; VIRUS ATTENUATION; VIRUS LATENCY; VIRUS REPLICATION;

EID: 0031984639     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.72.1.442-451.1998     Document Type: Article

References (76)

1. Adler, S. P., S. E. Starr, S. A. Plotkin, S. H. Henipfling, J. Buis, M. L. Manning, and A. M. Best. 1995. Immunity induced hy primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J. Infect. Dis. 171:26-32.
2. Ahn, K., A. Angulo, P. Ghazal, P. A. Peterson, Y. Yang, and K. Fruh. 1996. Human cytomegalovirus inhibits antigen presentation by a sequential multistep process. Proc. Natl. Acad. Sci. USA 93:10990-10995.
3. Armas, J. C. G., C. S. Morello, L. D. Cranmer, and D. H. Spector. 1996. DNA immunization confers protection against murine cytomegalovirus infection. J. Virol. 70:7921-7928.
4. Barkon, M. L., B. L. Haller, and H. W. Virgin. 1996. Circulating immunoglobulin G can play a critical role in clearance of intestinal reovirus infection. J. Virol. 70:1109-1116.
5. Bia, F. J., S. A. Miller, H. L. Lucia, B. P. Griffith, M. Tarsio, and G. D. Hsiung. 1984. Vaccination against transplacental cytomegalovirus transmission, vaccine reactivation and efficacy in guinea pigs. J. Infect. Dis. 149:355-362.
6. Booth, T. W., A. A. Scalzo, C. Carello, P. A. Lyons, H. E. Farrell, G. R. Singleton, and G. R. Shellam. 1993. Molecular and biological characterization of new strains of murine cytomegalovirus isolated from wild mice. Arch. Virol. 132:209-220.
7. Bosma, M. J. 1989. The scid mutation: occurrence and effect. Curr. Top. Microbiol. Immunol. 152:3-9.
8. Britt, W., J. Fay, J. Seals, and C. Kensil. 1995. Formulation of an immunogenic human cytomegalovirus vaccine: responses in mice. J. Infect. Dis. 171: 18-25.
9. Britt, W. J., and C. A. Alford. 1996. Cytomegalovirus, p. 2493-2523. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology. Lippincott-Raven, Philadelphia, Pa.
10. Campbell, A. E., J. S. Slater, V. J. Cavanaugh, and R. M. Stenberg. 1992. An early event in murine cytomegalovirus replication inhibits presentation of cellular antigens to cytotoxic T lymphocytes. J. Virol. 66:3011-3017.
11. Cavanaugh, V. J., R. M. Stenherg, T. L. Staley, H. W. Virgin, M. R. MacDonald, S. Paetzold, H. E. Farrell, W. D. Rawlinson, and A. E. Campbell. 1996. Murine cytomegalovirus with a deletion spanning HindIII-J and -I displays altered cell and tissue tropism. J. Virol. 70:1365-1374.
12. Chandler, S. H., H. H. Handsfield, and J. K. McDougall. 1987. Isolation of multiple strains of cytomegalovirus from women attending a clinic for sexually transmitted diseases. J. Infect. Dis. 155:655-660.
13. Cranmer, L. D., C. L. Clark, C. S. Morello, H. E. Farrell, W. D. Rawlinson, and D. H. Spector. 1996. Identification, analysis, and evolutionary relationships of the putative murine cytomegalovirus homologs of the human cytomegalovirus UL82 (pp71) and ULS3 (pp65) matrix phosphoproteins. J. Virol. 70:7929-7939.
14. Del Val, M., H. Hengel, H. Hacker, U. Hartlaub, T. Ruppert, P. Lucin, and U. H. Koszinowski. 1992. Cytomegalovirus prevents antigen presentation by blocking the transport of peptide-loaded major histocompatibility complex class I molecules into the medial-Golgi compartment. J. Exp. Med. 176:729-738.
15. DelVal, M., K. Munch, M. J. Reddehase, and V. H. Koszinowski. 1989. Presentation of CMV immediate-early antigen to cytolytic T lymphocytes is selectively prevented by viral genes expressed in the early phase. Cell 58: 305-315.
16. DelVal, M., H.-J. Schlicht, H. Volkmer, M. Messerle, M. J. Reddehase, and U. H. Koszinowski. 1991. Protection against lethal cytomegalovirus infection by a recombinant vaccine containing a single nonomeric T-cell epitope. J. Virol. 65:3641-3646.
17. DelVal, M., H. J. Schlicht, T. Ruppert, M. J. Reddehase, and U. H. Koszinowski. 1991. Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein. Cell 66:1145-1153.
18. DelVal, M., H. Volkmer, J. B. Rothbard, S. Jonjic, M. Messerle, J. Schickedanz, M. J. Reddehase, and U. H. Koszinowski. 1988. Molecular basis for cytolytic T-lymphocyte recognition of the murine cytomegalovirus immediate-early protein pp89. J. Virol. 62:3965-3972.
19. Dobbins, J. G., J. A. Stewart, and G. J. Demmler. 1992. Surveillance of congenital cytomegalovirus disease, 1990-1991. Morbid. Mortal. Weekly Rep. 41:35-44.
20. Eizuru, Y., and Y. Minamishima. 1979. Co-variation of pathogenicity and antigenicity in murine cytomegalovirus. Microbiol. Immunol. 23:559-564.
21. Farrell, H. E., and G. R. Shellam. 1991. Protection against murine cytomegalovirus infection by passive transfer of neutralizing and non-neutralizing monoclonal antibodies. J. Gen. Virol. 72:149-156.
22. Fleisher, G. R., S. E. Starr, H. M. Friedman, and S. A. Plotkin. 1982. Vaccination of pediatric nurses with live attenuated cytomegalovirus. Am. J. Dis. Child. 136:294-296.
23. Gesser, R. M., and S. C. Koo. 1996. Oral inoculation with herpes simplex virus type 1 infects enteric neurons and mucosal nerve fibers within the gastrointestinal tract in mice. J. Virol. 70:4097-4102.
24. Heise, M. T., and H. W. Virgin. 1995. The T cell independent rule of gamma interferon and tumor necrosis factor alpha in macrophage activation during murine cytomegalovirus and herpes simplex virus infection. J. Virol. 69:904-909.
25. Hengel, H., P. Lucin, S. Jonjic, T. Ruppert, and U. H. Koszinowski. 1994. Restoration of cytomegalovirus antigen presentation by gamma interferon combats viral escape. J. Virol. 68:289-297.
26. Howard, R. J., and H. H. J. Balfour. 1977. Prevention of morbidity and mortality of wild murine cytomegalovirus by vaccination with attenuated cytomegalovirus. Proc. Soc. Exp. Biol. Med. 156:365-368.
27. Huang, E.-S., C. A. Alford, D. W. Reynolds, S. Stagno, and R. F. Pass. 1980. Molecular epidemiology of cytomegalovirus infections in women and their infants. N. Engl. J. Med. 303:958-962.
28. Huang, E.-S., S.-M. Huong, G. E. Tegtemeier, and C. Alford. 1980. Cytomegalovirus: genetic variation of viral genomes. Ann. N. Y. Acad. Sci. 354: 332-346.
29. Huang, S., W. Hendriks, A. Althage, S. Hemmi, H. Bluethmann. R. Kamijo, J. Vilcek, R. M. Zinkernagel, and M. Aguet. 1993. Immune response in mice that lack the interferon-gamma receptor. Science 259:1742-1745.
30. Ibusuki, K., K. Kumura, and Y. Minamishima. 1993. Pathogenicity of murine cytomegalovirus for newborn mice: analysis with the attenuated mutants. Arch. Virol. 131:127-139.
31. Istas, A. S., G. J. Demmler, J. G. Dobbins, J. A. Stewart, and National Congenital Cytomegalovirus Disease Registry Collaborating Group. 1995. Surveillance for congenital cytomegalovirus disease: a report from the national congenital cytomegalovirus disease registry. Clin. Infect. Dis. 20:665-670.
32. Jones, T. R., L. K. Hanson, L. Sun, J. S. Slater, R. M. Stenberg, and A. E. Campbell. 1995. Multiple independent loci within the human cytomegalovirus unique short region down-regulate expression of major histocompatibiity complex class I heavy chains. J. Virol. 69:4830-4841.
33. Jonjic, S., M. DelVal, G. M. Keil, M. J. Reddehase, and U. H. Koszinowski. 1988. A nonstructural viral protein expressed by a recombinant vaccinia virus protects against lethal cytomegalovirus infection. J. Virol. 62:1653-1658.
34. Jonjic, S., W. Mutter, F. Weiland, M. J. Reddehase, and U. H. Koszinowski. 1989. Site-restricted persistent cytomegalovirus infection after selective long term depletion of CD4+ T lymphocytes. J. Exp. Med. 169:1199-1212.
35. Jonjic, S., I. Pavic, P. Lucin, D. Rukavina, and U. H. Koszinowski. 1990. Efficacious control of cytomegalovirus infection after long-term depletion of CD8+ T lymphocytes. J. Virol. 64:5457-5464.
36. Jonjic, S., I. Pavic, B. Polic, I. Crnkovic, P. Lucin, and U. H. Koszinowski. 1994. Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus. J. Exp. Med. 179:1713-1717.
37. Jordan, M. C., and V. L. Mar. 1982. Spontaneous activation of latent cytomegalovirus from murine spleen explants: role of lymphocytes and macrophages in release and replication of virus. J. Clin. Invest. 70:762-768.
38. Kitamura, D., J. Roes, R. Kuhn, and K. Rajewsky. 1991. A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. Nature 350:423-426.
39. Koller, B. H., P. Marrack, J. W. Kappler, and O. Smithies. 1990. Normal development of mice deficient in beta 2M, MHC class I proteins, and CDS+ T cells. Science 248:1227-1230.
40. Koszinowski, U. H., G. M. Keil, H. Schwarz, J. Schickedanz, and M. J. Reddehase. 1987. A nonstructural polypeptide encoded by immediate-early transcription unit 1 of murine cytomegalovirus is recognized by cytolytic T lymphocytes. J. Exp. Med. 166:289-294.
41. Kumura, K., K. Ibusuki, and Y. Minamishima. 1990. Independent existence of mutations responsible for temperature sensitivity and attenuation in a mutant of murine cytomegalovirus. Virology 175:572-574.
42. Lucin, P., I. Pavic, B. Polic, S. Jonjic, and U. H. Koszinowski. 1992. Gamma interferon-dependent clearance of cytomegalovirus infection in salivary glands. J. Virol. 66:1977-1984.
43. McFarlane, E. S., and R. W. Koment. 1986. Use of restriction endonuclease digestion to analyze strains of human cytomegalovirus isolated concurrently from an immunocompetent heterosexual man. J. Infect. Dis. 154:167-168.
44. Mercer, J. A., C. A. Wiley, and D. H. Spector. 1988. Pathogenesis of murine cytomegalovirus infection: identification of infected cells in the spleen during acute and latent infections. J. Virol. 62:987-997.
45. Minamishima, Y. 1977. Immunoprophylaxis of experimental cytomegalovirus infection. Ann. Microbiol. (Paris) 128:399-407.
46. Minamishima, Y., Y. Eizuru, A. Yoshida, and R. Fukunishi. 1978. Murine model for immunoprophylaxis of cytomegalovirus infection. I. Efficacy of immunization. Microbiol. Immunol. 22:693-700.
47. Morrison, L. A., and D. M. Knipe. 1994. Immunization with replication-defective mutants of herpes simplex virus type 1: sites of immune intervention in pathogenesis of challenge virus infection. J. Virol. 68:689-696.
48. Morrison, L. A., and D. M. Knipe. 1996. Mechanisms of immunization with a replication-defective mutant of herpes simplex virus 1. Virol. 220:402-413.
49. Orange, J. S., B. Wang, C. Terhorst, and C. A. Biron. 1995. Requirement for natural killer cell-produced interferon-gamma in defense against murine cytomegalovirus infection and enhancement of this defense pathway by interleukin 12 administration. J. Exp. Med. 182:1045-1056.
50. Osborn, J. E., and D. L. Walker. 1970. Virulence and attenuation of murine cytomegalovirus. Infect. Immun. 3:228-236.
51. Plotkin, S. A., H. M. Friedman, G. R. Fleisher, D. C. Dafoe, R. A. Grossman, M. L. Smiley, S. E. Starr, C. Wlodaver, A. D. Friedman, and C. F. Barker. 1984. Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants. Lancet ii:528-530.
52. Plotkin, S. A., R. Higgins, J. B. Kurtz, P. J. Morris, D. A. Campbell, T. C. Shope, S. A. Spector, and W. M. Dankner. 1994. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation 58:1176-1178.
53. Plotkin, S. A., S. E. Starr, H. M. Friedman, E. Gonczol, and R. E. Weibel. 1989. Protective effects of towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge. J. Infect. Dis. 159:860-865.
54. Plotkin, S. A., R. E. Weibel, G. Alpert, S. E. Starr, H. M. Friedman, S. R. Preblud, and J. Hoxie. 1985. Resistance of seropositive volunteers to subcutaneous challenge with low-passage human cytomegalovirus. J. Infect. Dis. 151:737-739.
55. Pollock, J. L., R. M. Presti, S. Paetzold, and H. W. Virgin. 1997. Latent murine cytomegalovirus infection in macrophages. Virology 227:168-179.
56. Pollock, J. L., and H. W. Virgin. 1995. Latency, without persistence, of murine cytomegalovirus in spleen and kidney. J. Virol. 69:1762-1768.
57. Porath, A., R. A. Menutt, L. M. Smiey, and K. A. Weigle. 1990. Effectiveness and cost benefit of a proposed live cytomegalovirus vaccine in the prevention of congenital disease. Rev. Infect. Dis. 12:31-40.
58. Quinnan, G. V., N. Kirmani, A. H. Rook, J. F. Manischewitz, L. Jackson, G. Moreschi, G. W. Santos, R. Saral, and W. H. Burns. 1982. Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N. Engl. J. Med. 307:7-13.
59. Reddehase, M. J., M. Baltheson, M. Rapp, S. Jonjic, I. Pavic, and U. H. Koszinowski. 1994. The conditions of primary infection define the load of latent viral genome in organs and the risk of recurrent cytomegalovirus disease. J. Exp. Med. 179:185-193.
60. Reddehase, M. J., S. Jonjic, F. Weiland, W. Mutter, and U. H. Koszinowski. 1988. Adoptive immunotherapy of murine cytomegalovirus adrenalitis in the immunocompromised host: CD4-helper-independent antiviral function of CDS-positive memory T lymphocytes derived from latently infected donors. J. Virol. 62:1061-1065.
61. Reddehase, M. J., G. M. Keil, and U. H. Koszinowski. 1984. The cytolytic T lymphocyte response to the murine cytomegalovirus. II. Detection of virus replication stage-specific antigens by separate populations of in vivo active cytolytic T lymphocyte precursors. Eur. J. Immunol. 14:56-61.
62. Reddehase, M. J., W. Mutter, K. Munch, H. J. Buhring, and U. H. Koszinowski. 1987. CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity. J. Virol. 61: 3102-3108.
63. Scalzo, A. A., S. L. Elliott, J. Cox, J. Gardner, D. J. Moss, and A. Suhrbier. 1995. Induction of protective cytotoxic T cells to murine cytomegalovirus by using a nonapcptide and a human-compatible adjuvant (montanide ISA 720). J. Virol. 69:1306-1309.
64. Smiley, M. L., C. G. Wlodaver, R. A. Grossman, C. F. Barker, L. J. Perloff, N. B. Tustin, S. E. Starr, S. A. Plotkin, and H. M. Friedman. 1985. The role of pretransplant immunity in protection from cytomegalovirus disease following renal transplantation. Transplantation 40:157-161.
65. Smith, S. C., and P. M. Allen. 1991. Myosin-induced acute myocarditis is a T cell-mediated disease. J. Immunol. 147:2141-2147.
66. Starr, S. E., H. M. Friedman, and S. A. Plotkin. 1991. The status of cytomegalovirus vaccine. Rev. Infect. Dis. 13(Suppl. 11):S964-S965.
67. Tay, C. H., and R. M. Welsh. 1997. Distinct organ-dependent mechanisms for the control of murine cytomegalovirus infection by natural killer cells. J. Virol. 71:267-275.
68. Thale, R., U. Szepan, H. Hengel, G. Geginat, P. Lucin, and U. H. Koszinowski. 1995. Identification of the mouse cytomegalovirus genomic region affecting major histocompatibility complex class I molecule transport. J. Virol. 69:6098-6105.
69. Tonari, Y., and Y. Minamishima. 1983. Pathogenicity and immunogenicity of temperature-sensitive mutants of murine cytomegalovirus. J. Gen. Virol. 64:1983-1990.
70. Tyler, K. L., M. A. Mann, B. N. Fields, and H. W. Virgin. 1993. Protective anti-reovirus monoclonal antibodies and their effects on viral pathogenesis. J. Virol. 67:3446-3453.
71. Virgin, H. W., and K. L. Tyler. 1991. Role of immune cells in protection against and control of reovirus infection in neonatal mice. J. Virol. 65:5157-5164.
72. Volkmer, H., C. Bertholet, S. Jonjic, R. Wittek, and U. H. Koszinowski. 1987. Cytolytic T lymphocyte recognition of the murine cytomegalovirus nonstructural immediate-early protein pp89 expressed by recombinanl vaccinia virus. J. Exp. Med. 166:668-677.
73. Walter, E. A., P. D. Greenberg, M. J. Gilbert, R. J. Finch, K. S. Watanabe, E. D. Thomas, and S. R. Riddell. 1995. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333:1038-1044.
74. Welsh, R. M., J. O. Brubaker, M. Vargas Cortes, and C. L. O'Donnell. 1991. Natural killer (NK) cell response to virus infections in mice with severe combined immunodeficiency. The stimulation of NK cells and the NK cell-dependent control of virus infections occur independently of T and B cell function. J. Exp. Med. 173:1053-1063.
75. Winston, D. J., W. G. Ho, C.-H. Lin, K. Bartoni, M. D. Budinger, R. P. Gale, and R. E. Champlin. 1987. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann. Intern. Med. 106:12-18.
76. Yamashita, Y., K. Shimokata, S. Mizuno, H. Yamaguchi, and Y. Nishiyama. 1993. Down-regulation of the surface expression of class I MHC antigens by human cytomegalovirus. Virology 193:727-736.